Maybe, but the press release it typical bullskat.
1. The Aegea test should had an EUA last yr but Nall was incompetent and didn't think Covid testing would last. Because of that they now have had to get cleared which caused delays. A test last September would have had a greater meaining pre vaccine rollout
2. This press release is no different than the one in August that was used to pump the stock to get enough votes to approve a reverse split. Nall tanked the stock with a reverse split and then gave himself 241,000 options at 75% less than the price per share of the first aegea announcement
3. The stock price was higher last febuary before Nall announced Covid testing, the BS VEESure, the Aegea announcements or the new hospital affilaitions for the liquid biopsy.
4. Nall, kennedy and the BOD committed fraud, and the outside attorney and auditor must be in on it because they have not corrected it. Probably because of the class action lawsuit that will have a couple of these execs working a $10.00 an hour job.
Biocept is a good company, lots of hard working people. Stay tuned. I am long till earnings.
This will be the month of pumps and then massive financing because they bleed cash even with Covid testing revenues.
The Aegea announcement does not give them and excusive to sell the test nor does it give them any patent ownership. Typical Biocept press release.
News 
Market Data 
Discover 
